. Putative frataxin ubiquitination inhibitors/competitors yield no effect on endogenous mature frataxin protein enrichment. We evaluated if a more targeted approach can modulate FXN levels. Two previous reports suggested that pFXN is a UPP substrate and utilized computational screening approaches to identify putative ubiquitination inhibitors of FXN 1,2 . A) We tested the effect of putative FXN ubiquitination inhibitor CPD11 1 on endogenous mFXN levels. A dose-response study using the racemic mixture of CPD11 in 293T cells failed to yield any significant effect on precursor, intermediate or mature FXN levels. B) We then explored the potential ability of a combination approach of CPD11 with UAEi or BTZ to enrich cells with mFXN. We reasoned that this combination treatment may potentiate a stabilization of pFXN effect. Cells were subjected to a 24 h treatment with CPD11 and supplemented with UAEi or BTZ during the last 6 h or incubation. Western analysis of the lysates demonstrated robust accumulation or loss of polyubiquitinated proteins upon treatment with BTZ or UAEi, respectively. However, consistent with previous experiments using BTZ or UAEi (Figure 3) , we only observed a decrease in iFXN but no change in endogenous mFXN levels. C) We attempted to isolate the putative active CPD11 enantiomer but were unsuccessful due to rapid decomposition in less than 10 min at both 20°C and 37°C at physiological or near physiological pH. D) We also tested a representative molecule, 620301, from another class of putative FXN ubiquitination inhibitor molecules 2 for its ability to increase endogenous mFXN. Lymphoblasts heterozygous for the GAA expansion in intron 1 of FXN (GM15849) or homozygous for the expansions (GM15850) and a healthy match (AG14725) were subjected to a dose-response treatment with 620301 for 5 days. Similar to the results for CPD11, no changes to pFXN, iFXN or mFXN levels were observed by western analysis in any of the lymphoblast lines. Figure S2 . Inhibition of the UPP alters overexpressed precursor and intermediate but not mature FXN protein levels. To test the effect of UPP inhibition on overexpressed FXN, 293T cells were seeded in 6-well plates and co-transfected with 0.2 µg hFXN plasmid and 0.1 µg GFP expression construct per well for 24 h (supplemented to 1 µg total plasmid per well with EV) before being subjected to a 16 h treatment with the indicated final concentrations of UAEi, BTZ, MG132, or DMSO vehicle. Cells were harvested and analyzed by immunoblotting.
. Inhibition of the UPP alters overexpressed precursor and intermediate but not mature FXN protein levels. To test the effect of UPP inhibition on overexpressed FXN, 293T cells were seeded in 6-well plates and co-transfected with 0.2 µg hFXN plasmid and 0.1 µg GFP expression construct per well for 24 h (supplemented to 1 µg total plasmid per well with EV) before being subjected to a 16 h treatment with the indicated final concentrations of UAEi, BTZ, MG132, or DMSO vehicle. Cells were harvested and analyzed by immunoblotting. Figure S3 . Precursor frataxin can be modestly increased by proteasome inhibitors but no ubiquitinated FXN could be detected in our system. A) 293T cells were treated for 24 h with BTZ or MG132 (10 µM) and corresponding lysates were analyzed by western blotting. All three forms of FXN (precursor, intermediate, and mature) are detected. B) Lysates from 293T cells treated with 10 µM BTZ for 24 h were subjected to an anti-FXN immunoprecipitation reaction using anti-FXN (abcam, ab110328) DSS cross-linked beads. Input lysates (Input), immunoprecipitates (IP) and flowthrough (FT) were analyzed by western blotting as indicated. C) 293T cells treated with 10 µM DBeQ, 10 µM BTZ, or 0.1% DMSO vehicle were harvested in NEM-containing lysis buffer, as detailed in methods, and subjected to immunoprecipitation with anti-FXN conjugated beads as in B). Beads were washed with high salt (500 mM NaCl, 50 mM Tris-HCl pH 7.5) buffer and low salt (10 mM TrisCl pH 7.5) buffers. Input lysates (Input), immunoprecipitates (IP), and flowthrough lysates (FT) were analyzed by immunoblotting as indicated. Tables   Supplementary Table 1 . List of individual siRNA oligo sequences. 
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